Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04216472
Title Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center

triple-receptor negative breast cancer


Alpelisib + Nab-paclitaxel

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST